Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | -1.39% | 43.85 | 0.9% | $1523.47m | |
| ABBV | AbbVie, Inc. | -0.39% | 107.66 | 1.9% | $991.05m | |
| JNJ | Johnson & Johnson | -0.36% | 164.62 | 0.7% | $987.18m | |
| MRK | Merck & Co., Inc. | -0.50% | 71.61 | 0.7% | $796.28m | |
| LLY | Eli Lilly & Co. | -0.47% | 229.96 | 1.1% | $594.20m | |
| BMY | Bristol-Myers Squibb Co. | 0.03% | 61.25 | 1.0% | $551.71m | |
| AZN | AstraZeneca Plc | -1.84% | 55.56 | 1.0% | $261.07m | |
| NVS | Novartis AG | -1.08% | 83.47 | 0.2% | $168.99m | |
| SNY | Sanofi | 0.39% | 48.38 | 0.2% | $137.69m | |
| GSK | GlaxoSmithKline Plc | -0.44% | 38.94 | 0.2% | $122.91m | |
| RPRX | Royalty Pharma Plc | 0.31% | 38.50 | 0.1% | $119.08m | |
| NVO | Novo Nordisk A/S | -0.94% | 101.42 | 0.1% | $109.34m | |
| VTRS | Viatris, Inc. | -0.88% | 13.57 | 0.0% | $109.22m | |
| RGEN | Repligen Corp. | 2.34% | 306.90 | 6.8% | $102.98m | |
| APLS | Apellis Pharmaceuticals, Inc. | 0.62% | 34.21 | 0.0% | $96.93m |
Company Profile
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.